Date: 2015-06-15
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the Cell Symposia, \'Cancer, Inflammation and Immunity\' in Sitges, Spain
Company: Heat Biologics (USA - NC)
Product: Combination Pan-Antigen Cytotoxic Therapy (ComPACT - Combination Immunotherapy Platform)
Action
mechanism: immunotherapy product
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On June 15, 2015, Heat Biologics, a clinical stage cancer immunotherapy company, announced the development of its next-generation combination immunotherapy platform, which combines a pan-antigen T cell priming vaccine and T cell co-stimulator in a single product. This platform, named ComPACT, has been engineered to incorporate various fusion proteins targeting co-stimulatory receptors (OX40, ICOS, 4-1BB), enabling the combination of two important immunotherapy pathways in a single therapy. Data generated using the ComPACT platform are being presented at the Cell Symposia, \'Cancer, Inflammation and Immunity\' in Sitges, Spain. The presentation by George Fromm, PhD, Heat\'s Director of Research, reveals the first preclinical analysis of ComPACT, incorporating OX40L-Fc, demonstrates significant benefits as compared to traditional OX40 agonistic antibodies. Dr. Fromm commented: \"The magnitude of T cell stimulation with ComPACT was somewhat unexpected, but clearly demonstrates substantial increases for both primary and memory immune response to those seen by co-administration of a vaccine and OX40 agonist antibody.\" The data illustrate that systemic OX40 stimulation through antibody therapy led to increased off-target T cell activation, and that the beneficial response with ComPACT may be due to increased specificity. Although the data presented include combinations between gp96-Ig vaccination and stimulation of OX40, the platform has also been developed to target other T cell co-stimulatory receptors including ICOS, 4-1BB and other undisclosed co-stimulatory targets. Heat expects to file its first IND with the ComPACT platform in 2H, 2016.
